Drugs / ISIS 388626
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00836225 | Jan 2009 → Oct 2011 | type 2 diabetes mellitus | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2009-06-09 | Ionis Pharmaceuticals | Results Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions ionis.com ↗
Isis' scientists presented new preclinical data on ISIS-SGLT2Rx showing a robust and sustained reduction in sodium dependent glucose co-transporter type 2 (SGLT2) levels that resulted in a significant reduction in blood glucose levels in multiple animal species. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2009-06-09 | Ionis Pharmaceuticals | Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions ionis.com ↗ |
| 2007-10-18 | Ionis Pharmaceuticals | Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes ionis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISIS 388626 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00836225 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT00836225 ↗ |